Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rhone Ma Holdings BhdXKLS:5278 61 Return-on-Tangible-Equity is 7.88% as of Mar. 2026, which is 10% below its 10-year median of 8.77. GuruFocus rates XKLS:5278 with a GF Score™ of 61/100 and a GF Value™ of RM0.90 (Modestly Undervalued). Among 901 Drug Manufacturers companies, Rhone Ma Holdings Bhd ranks better than 51.5% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Rhone Ma Holdings Bhd's annualized net income for the quarter that ended in Mar. 2026 was RM13.7 Mil. Rhone Ma Holdings Bhd's average shareholder tangible equity for the quarter that ended in Mar. 2026 was RM174.1 Mil. Therefore, Rhone Ma Holdings Bhd's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 7.88%.
The historical rank and industry rank for Rhone Ma Holdings Bhd's Return-on-Tangible-Equity or its related term are showing as below:
XKLS:5278'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 6.4 Med: 8.77 Max: 14.07
Current: 8.33
During the past 13 years, Rhone Ma Holdings Bhd's highest Return-on-Tangible-Equity was 14.07%. The lowest was 6.40%. And the median was 8.77%.
XKLS:5278's Return-on-Tangible-Equity is ranked better than 51.5% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs XKLS:5278: 8.33
Rhone Ma Holdings Bhd (XKLS:5278) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Rhone Ma Holdings Bhd Return-on-Tangible-Equity Related Terms
Rhone Ma Holdings Bhd Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Rhone Ma Holdings Bhd's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rhone Ma Holdings Bhd Return-on-Tangible-Equity Chart
XKLS:5278 vs ZTS, UTHR, VTRS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Rhone Ma Holdings Bhd's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rhone Ma Holdings Bhd Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rhone Ma Holdings Bhd's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Rhone Ma Holdings Bhd's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 7.88% mean?
Rhone Ma Holdings Bhd (XKLS:5278) has a Return-on-Tangible-Equity of 7.88% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Rhone Ma Holdings Bhd and its competitors. This is 10% below median its historical median of 8.77. Over the past decade, Rhone Ma Holdings Bhd's Return-on-Tangible-Equity has ranged from 6.40 to 14.07. According to the industry distribution chart, Rhone Ma Holdings Bhd ranks #437 out of 901 companies in the Drug Manufacturers industry, placing it in the top 48.5%.
Is Rhone Ma Holdings Bhd's Return-on-Tangible-Equity too high?
Rhone Ma Holdings Bhd's current Return-on-Tangible-Equity of 7.88% is 10% below median its 10-year median of 8.77. Over the past 10 years, this metric has ranged from a low of 6.40 to a high of 14.07. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Rhone Ma Holdings Bhd's value of 7.88% is 0.3% below this industry median. Based on the distribution chart, Rhone Ma Holdings Bhd ranks #437 out of 901 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Rhone Ma Holdings Bhd has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rhone Ma Holdings Bhd's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Rhone Ma Holdings Bhd ranks #437 out of 901 companies for Return-on-Tangible-Equity. This puts Rhone Ma Holdings Bhd in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.90. Rhone Ma Holdings Bhd's value of 7.88% is 0.3% below this benchmark. Historically, Rhone Ma Holdings Bhd's own Return-on-Tangible-Equity has ranged from 6.40 to 14.07 over the past decade. While the company's 10-year median is 8.77 vs. the industry median of 7.90, Rhone Ma Holdings Bhd has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rhone Ma Holdings Bhd's current Return-on-Tangible-Equity of 7.88% is 0.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Rhone Ma Holdings Bhd and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rhone Ma Holdings Bhd's current Return-on-Tangible-Equity is 7.88%, which is 10% below median its own 10-year median of 8.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhone Ma Holdings Bhd stock overvalued right now?
Based on GuruFocus' analysis, Rhone Ma Holdings Bhd (XKLS:5278) is currently considered Modestly Undervalued. The stock's GF Value™ is RM0.90, compared to a current price of RM0.70 — trading 22.2% below its estimated fair value. The current Return-on-Tangible-Equity is 7.88%, which is 10% below median its 10-year median of 8.77 and 0.3% below the Drug Manufacturers industry median of 7.90. Rhone Ma Holdings Bhd's overall GF Score™ is 61/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Rhone Ma Holdings Bhd (XKLS:5278), the current Return-on-Tangible-Equity is 7.88% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rhone Ma Holdings Bhd (XKLS:5278) Overvalued in 2026?
Based on GuruFocus' analysis, Rhone Ma Holdings Bhd stock appears to be undervalued.
The current stock price of RM0.70 is trading 22.2% below its estimated GF Value™ of RM0.90.
GuruFocus considers Rhone Ma Holdings Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:5278:
Return-on-Tangible-Equity: 7.88% (10% below median its 10-year median of 8.77)
GF Value™: RM0.90 vs. price of RM0.70 (22.2% below fair value)
Industry Position: 0.3% below the Drug Manufacturers median (#437 of 901)
No single metric tells the full story. See the XKLS:5278 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rhone Ma Holdings Bhd, along with its subsidiaries, is mainly involved in the provision of end-to-end animal health solutions. The Group provides veterinary consultation services, diagnostic laboratory analyses, R&D, and is engaged in the manufacturing and distribution of animal health products. Its reportable segments are: Animal health products and equipment, Food ingredients, and Others. The majority of its revenue is generated from the Animal health products and equipment segment, which is engaged in marketing, trading, distribution, and manufacturing of animal health products and equipment, such as pharmaceuticals, vaccines, feed additives, pesticides, and others. Geographically, the Group's operations are predominantly located in Malaysia.
61GF Score
Get the complete analysis for XKLS:5278
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:5278 has been successfully added to your 
